Latest Ratios: P/E Ratio -12.2x · EV/EBITDA N/A · ROE -38.9%. (2013–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $1.4B | $3.2B | $1.6B | $7.7B | $7.8B | $18.8B | $8.2B | $3.1B | $1.8B | $672M |
| Enterprise Value | $1.9B | $1.6B | $3.7B | $1.9B | $8.1B | $8.1B | $19.0B | $8.2B | $3.1B | $1.8B | $668M |
| P/E Ratio → | -12.25 | — | — | — | — | — | 961.33 | — | — | — | — |
| P/S Ratio | 2.64 | 2.20 | 5.31 | 3.12 | 14.27 | 14.51 | 38.11 | 23.32 | 12.39 | 10.10 | 8.10 |
| P/B Ratio | 4.89 | 4.23 | 8.92 | 4.38 | 17.40 | 18.92 | 39.54 | 37.62 | 27.39 | 15.75 | 4.72 |
| P/FCF | — | — | — | — | 814.09 | 132.55 | 223.81 | 507.85 | — | — | — |
| P/OCF | — | — | — | — | 249.35 | 93.84 | 190.02 | 307.82 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.48 | 6.17 | 3.82 | 15.15 | 15.21 | 38.52 | 23.29 | 12.43 | 10.21 | 8.06 |
| EV / EBITDA | — | — | — | — | — | — | 481.52 | 1094.13 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 533.70 | 1620.39 | — | — | — |
| EV / FCF | — | — | — | — | 863.82 | 138.91 | 226.24 | 507.16 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5% | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% | 74.8% | 67.7% | 68.6% | 44.2% |
| Operating Margin | -23.5% | -23.5% | -28.2% | -45.7% | -16.6% | -8.3% | 6.1% | -0.3% | -13.6% | -22.2% | -139.1% |
| Net Profit Margin | -20.8% | -20.8% | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% | -2.1% | -25.6% | -34.8% | -159.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.9% | -38.9% | -46.7% | -51.5% | -21.7% | -13.2% | 5.7% | -4.4% | -56.3% | -48.2% | -67.1% |
| ROA | -13.3% | -13.3% | -14.1% | -17.7% | -7.9% | -5.3% | 2.6% | -1.8% | -21.0% | -22.5% | -44.7% |
| ROIC | -16.4% | -16.4% | -16.0% | -21.5% | -7.9% | -4.5% | 5.1% | -0.4% | -19.9% | -21.8% | -59.0% |
| ROCE | -28.9% | -28.9% | -23.5% | -23.3% | -8.8% | -4.6% | 4.6% | -0.3% | -13.7% | -17.1% | -44.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 1.90 | 1.64 | 1.32 | 1.42 | 0.95 | 0.77 | 1.33 | 0.86 | 0.68 |
| Debt / EBITDA | — | — | — | — | — | — | 11.39 | 22.49 | — | — | — |
| Net Debt / Equity | — | 0.55 | 1.44 | 0.98 | 1.06 | 0.91 | 0.43 | -0.05 | 0.08 | 0.17 | -0.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | 5.17 | -1.50 | — | — | — |
| Debt / FCF | — | — | — | — | 49.73 | 6.35 | 2.43 | -0.70 | — | — | — |
| Interest Coverage | — | — | -10.36 | -38.41 | -9.68 | -5.50 | 1.98 | 0.34 | -1.92 | -3.15 | -16.55 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.90 | 2.90 | 1.46 | 5.78 | 7.00 | 7.53 | 8.80 | 5.10 | 4.98 | 4.88 | 7.10 |
| Quick Ratio | 2.71 | 2.71 | 1.42 | 5.56 | 6.82 | 7.36 | 8.56 | 4.82 | 4.63 | 4.44 | 6.41 |
| Cash Ratio | 2.05 | 2.05 | 1.27 | 5.08 | 6.11 | 6.58 | 7.52 | 3.80 | 3.81 | 3.65 | 5.96 |
| Asset Turnover | — | 0.81 | 0.49 | 0.44 | 0.45 | 0.47 | 0.47 | 0.73 | 0.73 | 0.67 | 0.29 |
| Inventory Turnover | 4.06 | 4.06 | 3.91 | 3.36 | 3.91 | 4.70 | 3.88 | 3.74 | 3.55 | 2.52 | 1.81 |
| Days Sales Outstanding | — | 64.24 | 61.56 | 55.26 | 71.95 | 66.45 | 74.18 | 66.45 | 53.74 | 60.96 | 27.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 0.1% | — | — | — | — |
| FCF Yield | — | — | — | — | 0.1% | 0.8% | 0.4% | 0.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $111M | $108M | $106M | $105M | $103M | $109M | $97M | $92M | $89M | $86M |
Includes 30+ ratios · 13 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVCR stock.
Novocure Ltd's current P/E ratio is -12.2x. This places it at the 50th percentile of its historical range.
Novocure Ltd's return on equity (ROE) is -38.9%. The historical average is -39.3%.
Based on historical data, Novocure Ltd is trading at a P/E of -12.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Novocure Ltd has 74.5% gross margin and -23.5% operating margin.
Key Metrics
Top Statement Risk
Dependence on LUNAR trial success
Metrics are mathematically derived from official filings.
Gross Margin Holds, Operating Leverage Emerges
According to recent SEC filings, NVCR's gross margin reached 77.6% in 2026Q2, up from 73.9% a year earlier, while operating margin improved to -5.8% from -24.9%, suggesting early operating leverage.
The gross margin expansion to 77.6% in 2026Q2, from 73.9% in 2025Q2, indicates stable pricing power and efficient manufacturing of disposable arrays. Operating margin improved dramatically to -5.8% from -24.9% year-over-year, reflecting revenue growth outpacing fixed cost increases. However, the persistent negative operating margin underscores that the company has not yet achieved scale to cover its heavy R&D and SG&A investments, which combined still consume 83% of revenue.
Return on Capital Still Negative but Improving
Based on reported figures, NVCR's ROIC improved to -1.7% in 2026Q2 from -10.2% in 2026Q1, and ROE improved to -4.7% from -21.2%, indicating a narrowing of losses relative to invested capital.
The improvement in ROIC and ROE is driven by a combination of higher revenue and a reduced asset base, as total assets contracted from $1.4B in 2025Q3 to $795M in 2026Q2. Despite the improvement, returns remain deeply negative, implying the company is still destroying value on a trailing basis. The trend suggests that if the LUNAR-driven growth continues, the company could approach breakeven returns within the next few quarters, but the sustainability depends on maintaining revenue momentum.
Working Capital Efficiency Improves with Negative CCC
As reported in financial statements, NVCR's cash conversion cycle improved to -131 days in 2026Q2 from -60 days in 2025Q2, driven by a DPO of 286 days, indicating strong supplier leverage.
The negative cash conversion cycle of -131 days in 2026Q2 reflects a significant extension in days payable outstanding to 286 days, which appears to be a deliberate strategy to conserve cash. DSO has improved to 59 days from 71 days a year earlier, suggesting better collection efficiency, while DIO remains elevated at 95 days, possibly reflecting inventory buildup for new indications. The negative CCC provides a source of working capital financing, but the reliance on extended payables may strain supplier relationships if growth slows.
Leverage Normalizes After Peak
According to recent SEC filings, NVCR's debt-to-equity ratio fell to 0.69 in 2026Q2 from a peak of 2.34 in 2025Q3, as total debt declined from $797.9M to $233.4M, improving balance sheet flexibility.
The sharp deleveraging from 2025Q3 to 2026Q2 suggests a deliberate reduction in debt, possibly funded by cash reserves or a refinancing event. Interest coverage remains negative due to operating losses, but the lower debt load reduces refinancing risk. However, the company still carries a net loss and a modest cash position of $93.7M, so the path to cash-flow breakeven remains critical; if growth decelerates, the company may need to raise additional capital, potentially dilutive.
Liquidity Buffer Strengthens but Remains Thin
Based on reported figures, NVCR's current ratio improved to 2.89 in 2026Q2 from 1.55 in 2025Q3, while cash stood at $93.7M, providing a modest buffer against near-term obligations.
The current ratio of 2.89 indicates that current assets cover current liabilities nearly three times, a comfortable level on paper. However, the absolute cash balance of $93.7M is relatively small relative to the quarterly operating loss of -$15.7M, implying a runway of roughly six quarters at the current burn rate. The improvement in liquidity is partly due to the reduction in debt, but the company's ability to withstand a prolonged downturn or a delay in the LUNAR ramp remains uncertain.
Misapplied Metric: EV/EBITDA
The most commonly misapplied ratio for NVCR is EV/EBITDA, which is meaningless given negative EBITDA; instead, investors should focus on price-to-sales and cash burn adjusted for stock-based compensation.
EV/EBITDA is frequently cited for NVCR, but with negative EBITDA, the ratio is undefined and provides no insight. A more appropriate metric is EV/Sales, which at 3.02 reflects the market's pricing of future growth, but this must be adjusted for the significant stock-based compensation that inflates operating cash flow. Investors should also monitor the cash conversion cycle and the trajectory of operating margin, as these better capture the underlying economics of the recurring-revenue model.